Corporate Profile August 2020
(WorldNews China)

FACTSHEET August 2020 KEY HIGHLIGHTS Well diversified mid-to-late stage pipeline with first-in-class drug candidates A highly experienced management team with extensive expertise in metabolic drug development Strong global partnerships secured for the most advanced clinical program, Imeglimin Two differentiated programs for NASH (PXL770 / PXL065), a large and growing disease worldwide Cash and cash equivalents as of June 30, 2020 were EUR 46.0 million (USD 51.5 million); cash runway into 2022 CONTACTS Corporate headquarters in Lyon, France Poxel also has subsidiaries in Tokyo, Japan, and in the Boston, Massachusetts area Thomas Kuhn CEO and Co-founder Anne Renevot Chief Financial Officer...